Cited 0 times in Scipus Cited Count

Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares

DC Field Value Language
dc.contributor.authorChoi, HJ-
dc.contributor.authorLee, CH-
dc.contributor.authorLee, JH-
dc.contributor.authorYoon, BY-
dc.contributor.authorKim, HA-
dc.contributor.authorSuh, CH-
dc.contributor.authorChoi, ST-
dc.contributor.authorSong, JS-
dc.contributor.authorJoo, HY-
dc.contributor.authorChoi, SJ-
dc.contributor.authorLee, JS-
dc.contributor.authorShin, KC-
dc.contributor.authorBaek, HJ-
dc.date.accessioned2018-07-27T00:52:07Z-
dc.date.available2018-07-27T00:52:07Z-
dc.date.issued2017-
dc.identifier.issn1756-1841-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/15576-
dc.description.abstractAIM: To evaluate treatment patterns and clinical factors affecting gout flare in South Korea.
METHODS: We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after.
RESULTS: The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8%. Colchicine (62.3%) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4%) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6%) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it >/= 6 months (42.9% vs. 26.3%, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the >/= 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007).
CONCLUSIONS: Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT.
-
dc.formatapplication/pdf-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHBiomarkers-
dc.subject.MESHDisease Progression-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFemale-
dc.subject.MESHGout-
dc.subject.MESHGout Suppressants-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHUric Acid-
dc.titleCurrent gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares-
dc.typeArticle-
dc.identifier.pmid25160939-
dc.contributor.affiliatedAuthor김, 현아-
dc.contributor.affiliatedAuthor서, 창희-
dc.type.localJournal Papers-
dc.identifier.doi10.1111/1756-185X.12422-
dc.citation.titleInternational journal of rheumatic diseases-
dc.citation.volume20-
dc.citation.number4-
dc.citation.date2017-
dc.citation.startPage497-
dc.citation.endPage503-
dc.identifier.bibliographicCitationInternational journal of rheumatic diseases, 20(4). : 497-503, 2017-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1756-185X-
dc.relation.journalidJ017561841-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
Files in This Item:
25160939.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse